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Gamma-hydroxybutyric acid (GHB) and its precursors 
gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) 
pose a serious threat to the health of (ab)users, and the aim 
of this letter is to start a discussion in order to increase 
awareness of their large abuse potential, especially in chemsex 
practices and sexual assaults. In addition, we would like to 
open a discussion about detection and control options.
GHB is a naturally occurring precursor to gamma-
aminobutyric acid (GABA) and a neurotransmitter that can 
affect serotonin (5-HT, hydroxitryptamine), noradrenaline 
(NA, norepinephrine), dopamine (DA), and acetylcholine 
(ACh) production. It has its own presynaptic G protein-
coupled receptor in the brain. In its natural form, GHB is 
present in the brain and body fluids at low concentrations.
As recreational or party drug of abuse it is known under the 
street name of liquid ecstasy and has a biphasic action: at low 
concentrations it produces euphoria and removes personal or 
social inhibition, whereas at higher concentrations it causes 
visual impairment, dizziness, lower body control, sleepiness/
drowsiness, short-term memory impairment, and 
unconsciousness. Recreational doses are relatively high in view 
of most sedatives and range between 1.8 and 2.7 g, but most 
people are completely sedated by higher doses (>4 g) (1). It can 
also produce empathy (empathogenic/entactogenic effects) and 
cause hallucinations, agitation, or aggression (2, 3).
Early effects of GHB resemble those of alcohol 
intoxication, and are often confused with drunkenness. Hence 
its reputation of a rape drug (4, 5). Regular use may lead to 
physical dependence and substance use disorder (6) and 
create tolerance, which means that users need to up the dosage 
to achieve the same effect.
Although GHB has been approved for the treatment of 
narcolepsy with catalepsy by the United States Food and 
Drug Administration (FDA) (7) and is currently controlled, 
its abuse continues through unlawful production in 
clandestine laboratories and illegal sales on the internet (6). 
As of late, its recreational use is being replaced by that of its 
prodrug GBL, which is cheaper and easier to obtain due to 
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several legal industrial applications. Its use, however, entails 
a higher risk of overdosing because of higher liposolubility 
and density. The first is responsible for GBL reaching higher 
plasma peak levels faster than an equimolar dose of GHB, 
whereas higher density means that smaller doses are needed, 
which are more difficult to measure. This narrows the safety 
margin between causing the desired effects and coma. 
Fortunately, however, these are also the reasons why GBL 
is seldom used undiluted. In addition, the effects of GBL 
depend on user’s genetic setup, that is, lactonase activity, as 
it can slow down the onset of its effects (8). The toll is high, 
however, as GHB and its precursors (GBL and 1,4 BD) have 
been involved in reports of poisoning, overdose, rape, 
seizures, coma, and even death (6).
GHB, GBL, and 1,4-BD are often used in combination 
with designer drugs such as synthetic cathinones (9–12). 
GHB is at times mixed with other substances to offset any 
unwanted effects or maximise the perceived benefits. There 
have been reports of intoxication in homosexual men who 
consumed GHB combined with sildenafil to enhance sexual 
effects, as part of chemsex practices (5, 13). Such practices, 
however, are not meant to dilute or cut a given drug with 
another substance (e.g. the way in which cutting agents and 
adulterants such as benzocaine, lidocaine, or levamisole are 
used by cocaine dealers to increase their profits by diluting 
the drug with cheaper substances) (14), but rather to maximise 
and prolong the effects.
GHB has a rapid elimination – four to six hours after 
ingestion regardless of the dose – and a narrow detection 
window (less than 12 hours in urine). Petersen et al. (15) 
have therefore proposed a new biomarker with a longer 
detection window – GHB-glucuronide. This GHB metabolite 
has successfully been spotted in several biological matrices 
(plasma, urine, hair, nails, cerebrospinal fluid, and whole 
blood) (16–18) through the use of hyphenated techniques, 
but its levels were minimal in virtually useless in all these 
studies irrespective of whether the parent drug had been 
administered as a medication or abused as recreational drug 
(15–21).
The development of hyphenated analytical techniques 
(17, 18) such as ultra-high performance liquid chromatography 
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tandem mass spectrometry (UHPLC-MS/MS) and gas 
chromatography tandem mass spectrometry (GC-MS/MS) 
is therefore crucial if we want to be able to identify GHB and 
its precursors in conventional and unconventional biological 
matrices, bearing in mind the current proposed cut-offs to 
distinguish between endogenous and exogenous GHB (22). 
In samples taken from living subjects these are 5 mg/L for 
blood and 10 mg/L for urine, whereas in post-mortem 
specimens they are 30 mg/L and 50 mg/L for peripheral and 
central blood, respectively and 10 mg/L for urine (22).
In conclusion, we urge the scientific community 
investigating GHB to focus on new alternative metabolites, 
such as the carboxylic glucuronated metabolite, that may 
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